BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical has established a strong financial outlook, projecting sales of approximately $1 billion for Voxzogo in 2026 and anticipating overall top-line growth to around $4 billion by 2028. The company’s unique position as the only approved enzyme replacement therapy for phenylketonuria (PKU) is expected to support lengthy growth and expand its patient base, despite competitive pressures. Furthermore, a robust pipeline of upcoming therapies, including BMN-333, coupled with ongoing business development activities, suggests a promising trajectory that could enhance investor sentiment and close valuation gaps in the upcoming years.

The financial outlook for BioMarin Pharmaceutical is hindered by several significant risks that may affect its stock performance. A potential decline in market share for its primary product Voxzogo in light of emerging competition, coupled with slower-than-expected commercial uptake and possible delays in the approval of late-stage pipeline candidates such as BMN-401, raises concerns. Additionally, long-term dilution risks and a disconnect between estimated enterprise value and current trading levels suggest a challenging path ahead for BioMarin's stock.